2′-5′ oligoadenylate synthetase 1 polymorphism is associated with prostate cancer

Cancer

Volumn 117, Issue 24, 2011, Pages 5509-5518

  Mandal, Sanjay ^a   Abebe, Fisseha ^a   Chaudhary, Jaideep ^a  

^a CLARK ATLANTA UNIVERSITY   (United States)

Author keywords

2 5 ; cancer; oligoadenylate synthetase 1; polymorphism; prostate; reference single nucleotide polymorphism 2660

Indexed keywords

2',5' OLIGOADENYLATE SYNTHETASE; ADENINE; ARGININE; GENOMIC DNA; GLYCINE; GUANOSINE; RIBONUCLEASE L; SERINE; OAS1 PROTEIN, HUMAN;

2',5' OLIGOADENYLATE SYNTHETASE GENE; ADULT; AFRICAN AMERICAN; AGE; AGED; AMINO ACID SUBSTITUTION; APOPTOSIS; ARTICLE; CANCER RISK; CASE CONTROL STUDY; CAUCASIAN; CELL GROWTH; CONTROLLED STUDY; GENE; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENOTYPE; HUMAN; HUMAN CELL; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROSTATE CANCER; RACE DIFFERENCE; SAMPLE SIZE; SINGLE NUCLEOTIDE POLYMORPHISM; ENZYMOLOGY; GENETIC PREDISPOSITION; GENETICS; GENOMICS; METABOLISM; MIDDLE AGED; PROSTATE TUMOR; RETROSPECTIVE STUDY; TUMOR CELL LINE;

2',5'-OLIGOADENYLATE SYNTHETASE; CASE-CONTROL STUDIES; CELL LINE, TUMOR; GENETIC PREDISPOSITION TO DISEASE; GENOMICS; GENOTYPE; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES;

EID: 82955233365     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.26219     Document Type: Article

References (39)

1. Hovanessian AG, Justesen J,. The human 2′-5′ oligoadenylate synthetase family: unique interferon-inducible enzymes catalyzing 2′-5′ instead of 3′-5′ phosphodiester bond formation. Biochimie. 2007; 89: 779-788. (Pubitemid 47001635)
2. Hovnanian A, Rebouillat D, Mattei MG, et al. The human 2′,5′-oligoadenylate synthetase locus is composed of 3 distinct genes clustered on chromosome 12q24.2 encoding the 100-, 69-, and 40-kDa forms. Genomics. 1998; 52: 267-277. (Pubitemid 28487485)
3. Zhou A, Hassel BA, Silverman RH,. Expression cloning of 2-5A-dependent RNAase: a uniquely regulated mediator of interferon action. Cell. 1993; 72: 753-765. (Pubitemid 23093883)
4. Naik S, Paranjape JM, Silverman RH,. RNase L dimerization in a mammalian 2-hybrid system in response to 2′,5′-oligoadenylates. Nucleic Acids Res. 1998; 26: 1522-1527. (Pubitemid 28291630)
5. Domingo-Gil E, Esteban M,. Role of mitochondria in apoptosis induced by the 2-5A system and mechanisms involved. Apoptosis. 2006; 11: 725-738. (Pubitemid 43876842)
6. Yaffe A, Schwarz Y, Hacohen D, Kinar Y, Nir U, Salzberg S,. Inhibition of 2-5A synthetase expression by antisense RNA interferes with interferon-mediated antiviral and antiproliferative effects and induces anchorage-independent cell growth. Cell Growth Differ. 1996; 7: 969-978. (Pubitemid 26360707)
7. Nilsen TW, Maroney PA, Baglioni C,. Double-stranded RNA causes synthesis of 2′,5′-oligo(A) and degradation of messenger RNA in interferon-treated cells. J Biol Chem. 1981; 256: 7806-7811. (Pubitemid 12232356)
8. Kajaste-Rudnitski A, Mashimo T, Frenkiel MP, Guenet JL, Lucas M, Despres P,. The 2′,5′-oligoadenylate synthetase 1b is a potent inhibitor of West Nile virus replication inside infected cells. J Biol Chem. 2006; 281: 4624-4637. (Pubitemid 43847721)
9. Kristiansen H, Scherer CA, McVean M, et al. Extracellular 2′-5′ oligoadenylate synthetase stimulates RNase L-independent antiviral activity: a novel mechanism of virus-induced innate immunity. J Virol. 2010; 84: 11898-11904.
10. Salzberg S, Hyman T, Turm H, et al. Ectopic expression of 2-5A synthetase in myeloid cells induces growth arrest and facilitates the appearance of a myeloid differentiation marker. Cancer Res. 1997; 57: 2732-2740. (Pubitemid 27283787)
11. Ghosh A, Sarkar SN, Rowe TM, Sen GC,. A specific isozyme of 2′-5′ oligoadenylate synthetase is a dual function proapoptotic protein of the Bcl-2 family. J Biol Chem. 2001; 276: 25447-25455.
12. Gomos JB, Rowe TM, Sarkar SN, Kessler SP, Sen GC,. The proapoptotic 9-2 isozyme of 2-5 (A) synthetase cannot substitute for the sperm functions of the proapoptotic protein, Bax. J Interferon Cytokine Res. 2002; 22: 199-206. (Pubitemid 34275487)
13. Carpten J, Nupponen N, Isaacs S, et al. Germline mutations in the ribonuclease L gene in families showing linkage with HPC1. Nat Genet. 2002; 30: 181-184.
14. Rennert H, Zeigler-Johnson CM, Addya K, et al. Association of susceptibility alleles in ELAC2/HPC2, RNASEL/HPC1, and MSR1 with prostate cancer severity in European American and African American men. Cancer Epidemiol Biomarkers Prev. 2005; 14: 949-957. (Pubitemid 40478562)
15. Wiklund F, Jonsson BA, Brookes AJ, et al. Genetic analysis of the RNasaL gene in hereditary, familial, and sporadic prostate cancer. Clin Cancer Res. 2004; 10: 7150-7156. (Pubitemid 39487699)
16. Xiang Y, Wang Z, Murakami J, et al. Effects of RNase L mutations associated with prostate cancer on apoptosis induced by 2′,5′- oligoadenylates. Cancer Res. 2003; 63: 6795-6801. (Pubitemid 37322961)
17. Andersen JB, Li XL, Judge CS, Zhou A, Jha BK, Shelby S, et al. Role of 2-5A-dependent RNase-L in senescence and longevity. Oncogene. 2007; 26: 3081-3088. (Pubitemid 46733645)
18. Silverman RH,. Implications for RNase L in prostate cancer biology. Biochemistry. 2003; 42: 1805-1812. (Pubitemid 36258654)
19. Wang L, McDonnell SK, Elkins DA, et al. Analysis of the RNASEL gene in familial and sporadic prostate cancer. Am J Hum Genet. 2002; 71: 116-123. (Pubitemid 34734712)
20. Noonan-Wheeler FC, Wu W, Roehl KA, et al. Association of hereditary prostate cancer gene polymorphic variants with sporadic aggressive prostate carcinoma. Prostate. 2006; 66: 49-56. (Pubitemid 43005948)
21. Knapp S, Yee LJ, Frodsham AJ, et al. Polymorphisms in interferon-induced genes and the outcome of hepatitis C virus infection: roles of MxA, OAS-1 and PKR. Genes Immun. 2003; 4: 411-419. (Pubitemid 38967606)
22. Li CZ, Kato N, Chang JH, et al. Polymorphism of OAS-1 determines liver fibrosis progression in hepatitis C by reduced ability to inhibit viral replication. Liver Int. 2009; 29: 1413-1421.
23. Min JY, Krug RM,. The primary function of RNA binding by the influenza A virus NS1 protein in infected cells: inhibiting the 2′-5′ oligo(A)synthetase/RNase L pathway. Proc Natl Acad Sci U S A. 2006; 103: 7100-7105.
24. Urosevic N,. Is flavivirus resistance interferon type I-independent? Immunol Cell Biol. 2003; 81: 224-229. (Pubitemid 36649269)
25. Yakub I, Lillibridge KM, Moran A, et al. Single nucleotide polymorphisms in genes for 2′-5′-oligoadenylate synthetase and RNase L in patients hospitalized with West Nile virus infection. J Infect Dis. 2005; 192: 1741-1748. (Pubitemid 41587824)
26. Behera AK, Kumar M, Lockey RF, Mohapatra SS,. 2′-5′ Oligoadenylate synthetase plays a critical role in interferon-gamma inhibition of respiratory syncytial virus infection of human epithelial cells. J Biol Chem. 2002; 277: 25601-25608. (Pubitemid 34951877)
27. Hamano E, Hijikata M, Itoyama S, et al. Polymorphisms of interferon-inducible genes OAS-1 and MxA associated with SARS in the Vietnamese population. Biochem Biophys Res Commun. 2005; 329: 1234-1239. (Pubitemid 40568701)
28. Fedetz M, Matesanz F, Caro-Maldonado A, et al. OAS1 gene haplotype confers susceptibility to multiple sclerosis. Tissue Antigens. 2006; 68: 446-449. (Pubitemid 44707058)
29. O'Brien M, Lonergan R, Costelloe L, et al. OAS1: a multiple sclerosis susceptibility gene that influences disease severity. Neurology. 2010; 75: 411-418.
30. Bonnevie-Nielsen V, Martensen PM, Justesen J, et al. The antiviral 2′,5′-oligoadenylate synthetase is persistently activated in type 1 diabetes. Clin Immunol. 2000; 96: 11-18. (Pubitemid 30447925)
31. Field LL, Bonnevie-Nielsen V, Pociot F, Lu S, Nielsen TB, Beck-Nielsen H,. OAS1 splice site polymorphism controlling antiviral enzyme activity influences susceptibility to type 1 diabetes. Diabetes. 2005; 54: 1588-1591. (Pubitemid 40586694)
32. Bonnevie-Nielsen V, Field LL, Lu S, et al. Variation in antiviral 2′,5′-oligoadenylate synthetase (2′5′AS) enzyme activity is controlled by a single-nucleotide polymorphism at a splice-acceptor site in the OAS1 gene. Am J Hum Genet. 2005; 76: 623-633. (Pubitemid 40432169)
33. Zhang J, Wheeler DA, Yakub I, et al. SNPdetector: a software tool for sensitive and accurate SNP detection [serial online]. PLoS Comput Biol. 2005; 1: e53.
34. Menashe I, Rosenberg PS, Chen BE,. PGA: power calculator for case-control genetic association analyses. BMC Genet. 2008; 9: 36.
35. Fears TR, Brown CC,. Logistic regression methods for retrospective case-control studies using complex sampling procedures. Biometrics. 1986; 42: 955-960. (Pubitemid 17134912)
36. Mullan PB, Hosey AM, Buckley NE, et al. The 2,5 oligoadenylate synthetase/RNaseL pathway is a novel effector of BRCA1- and interferon-gamma- mediated apoptosis. Oncogene. 2005; 24: 5492-5501. (Pubitemid 43080092)
37. He WW, Sciavolino PJ, Wing J, et al. A novel human prostate-specific, androgen-regulated homeobox gene (NKX3.1) that maps to 8p21, a region frequently deleted in prostate cancer. Genomics. 1997; 43: 69-77. (Pubitemid 27310524)
38. Lim JK, Lisco A, McDermott DH, et al. Genetic variation in OAS1 is a risk factor for initial infection with West Nile virus in man [serial online]. PLoS Pathog. 2009; 5: e1000321.
39. Tessier MC, Qu HQ, Frechette R, et al. Type 1 diabetes and the OAS gene cluster: association with splicing polymorphism or haplotype? J Med Genet. 2006; 43: 129-132. (Pubitemid 43259624)